Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin.
about
Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal KenyaComparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan childrenRole of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisininTheileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitorMolecular epidemiology and seroprevalence in asymptomatic Plasmodium falciparum infections of Malagasy pregnant women in the highlandsPrevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014.Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient.The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine.pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.K13-propeller Alleles, Mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015.Changing antimalarial drug sensitivities in Uganda.
P2860
Q28125914-7E9D1828-8C46-442F-A456-5FEA0427FAA9Q33947834-8C526362-7E67-4920-8ED5-2B5940A43E0BQ34597550-264BD8CC-BF70-4C5A-8183-7F103D04798AQ35030076-C4883307-6D3B-4B9E-A970-DF02B3C70B17Q35610130-366CB817-CF00-42BC-B446-FE9D9F9E1904Q37077079-AD5EA825-1F2C-41C7-87AA-123BC0406311Q37233322-AE6EFBD8-EEFB-4E26-91FF-C5EC3A51ECC5Q37267688-AEA62AF3-0806-48B9-8361-12501A51611AQ38529669-24CA40C5-BD30-4105-B3EC-52EC118E84F1Q39206934-A7A50D7D-6412-49DB-A82D-094A1C1A872FQ41911890-753CE0A5-6E68-4711-94C8-E17B682C1E36Q41911931-D784D198-FCB4-46A1-AFA7-AC596513F4F8
P2860
Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@en
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@nl
type
label
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@en
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@nl
prefLabel
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@en
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@nl
P2093
P2860
P50
P921
P356
P1476
Plasmodium falciparum Polymorp ...... ombination therapies in Benin.
@en
P2093
Abel Wakpo
Agnès Aubouy
Jean-François Faucher
Oumou Maïga-Ascofaré
Pascal Houzé
Sabina Dahlström
Sèm Ezinmègnon
P2860
P356
10.1128/AAC.01790-12
P407
P577
2013-10-07T00:00:00Z